Red Yeast Rice: Use and Hyponatremia Risk
Red yeast rice is used as a dietary supplement for lowering cholesterol, but there is no evidence linking it to hyponatremia—instead, recent reports demonstrate it causes acute kidney injury with Fanconi syndrome and proximal tubular damage.
Primary Use: Cholesterol Reduction
Red yeast rice (RYR) is a traditional fermented food product containing monacolins, particularly monacolin K (which is chemically identical to lovastatin), that inhibit HMG-CoA reductase to lower LDL cholesterol 1, 2. It has been studied as an alternative or add-on therapy to statins for dyslipidemia management 3. However, major cardiology guidelines do not recommend RYR for cardiovascular risk reduction due to insufficient long-term safety and efficacy data 4, 3.
Key Points on Efficacy:
- Clinical trials show RYR significantly lowers LDL-C and total cholesterol 5
- The 2013 ACC/AHA guidelines specifically noted that while one ASCVD outcomes trial used Xuezhikang (a red yeast rice extract), it was not available in the United States during their evidence review, so no recommendations were made regarding its use 4
- European guidelines acknowledge RYR as a nutraceutical under investigation but state "there are still few data to draw firm conclusions about their long-term safety and efficacy" 3
Hyponatremia: Not a Documented Adverse Effect
RYR does not cause hyponatremia. The documented adverse effects are entirely different and involve:
Actual Documented Adverse Effects:
Acute Kidney Injury with Fanconi Syndrome (most concerning recent finding):
- Multiple recent case reports from Japan (2024-2025) document AKI with proximal tubular damage 6, 7, 8, 9
- Patients present with hypokalemia, hypophosphatemia, and hypouricemia (not hyponatremia) 7, 8, 9
- Renal biopsy shows diffuse proximal tubular injury with loss of brush border, tubular flattening, and lumen dilation 8, 9
- One product ("Beni Koji Choleste Help") was linked to 76 deaths and 492 hospitalizations in Japan 9
Statin-like Adverse Effects:
- Myalgia and elevated creatine phosphokinase 10
- Rhabdomyolysis (rare but documented) 11, 10
- Hepatotoxicity/liver injury 11, 10
- Gastrointestinal and cutaneous reactions 10
Important Clinical Caveat:
The Italian surveillance system found that 70% of RYR adverse reactions occurred in women, with 13 cases requiring hospitalization 10. The safety profile appears similar to statins, though the occurrence of rhabdomyolysis and severe hepatitis is "extremely rare compared to statins" 11.
Critical Safety Concerns
Do not recommend RYR in clinical practice for several reasons:
- Lack of standardization: Products vary widely in monacolin K content and may contain contaminants like citrinin (a nephrotoxic mycotoxin) 2, 7
- Regulatory issues: The FDA prohibits sale of RYR products containing monacolin K as it's considered an unapproved drug, yet many remain on the market 2
- Recent kidney injury epidemic: The 2024-2025 Japanese cases represent a serious public health crisis with ongoing investigations 6, 9
- No guideline support: Neither ACC/AHA nor ESC guidelines recommend RYR for cardiovascular risk reduction 4, 3
Monitoring if Patient is Already Taking RYR:
If a patient presents taking RYR, immediately check: